| Authors: |
Hill AG; Tasman Oncology Research, Southport, Australia. andrewgrahamhill@gmail.com., Findlay MP; Discipline of Oncology, University of Auckland, Auckland, New Zealand., Burge ME; Royal Brisbane and Women's Hospital, Herston, Australia; University of Queensland, Queensland, Australia., Jackson C; Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Alfonso PG; Gregorio Marañón Hospital, Madrid, Spain., Samuel L; Aberdeen Royal Infirmary, Aberdeen, United Kingdom., Ganju V; Peninsula Oncology Centre, Frankston, Australia., Karthaus M; Staedtisches Klinikum Muenchen GmbH-Klinikum Neuperlach, Munich, Germany., Amatu A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Jeffery M; Canterbury Regional Cancer and Haematology Service, Christchurch, New Zealand., Bartolomeo MD; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bridgewater J; University College London Cancer Institute, London, UK., Coveler AL; University of Washington, Seattle, Washington., Hidalgo M; Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain., Kapp AV; Genentech, Inc., South San Francisco, California., Sufan RI; Genentech, Inc., South San Francisco, California., McCall BB; Genentech, Inc., South San Francisco, California., Hanley WD; Genentech, Inc., South San Francisco, California., Penuel EM; Genentech, Inc., South San Francisco, California., Pirzkall A; Genentech, Inc., South San Francisco, California., Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain. |
